JERUSALEM , Feb. 19, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies in tablet [...] Read more »
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD–19 x FcγRIIb inhibitor of B cell function–
–Topline results from Phase 2 Trial in [...] Read more »
BioAro launches AI-Driven PanOmiQ with Ultrafast Whole Genome Sequencing Analysis Technology
CALGARY, Alberta, Feb. 03, 2025 (GLOBE NEWSWIRE) — Read more »
شركة BioAro تطلق تقنية تحليل تسلسل الجينوم الكامل فائقة السرعة PanOmiQ المدعومة بالذكاء الاصطناعي
كالجاري، ألبرتا،, Feb. 03, 2025 (GLOBE NEWSWIRE) —
ستكشف [...] Read more »
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical–stage global biopharmaceutical company committed to being a [...] Read more »
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, [...] Read more »
Brains Bioceutical élargit son offre de cannabinoïdes leaders sur le marché avec le D9-THC et le CBN, et ouvre ainsi de nouvelles possibilités en matière de développement de médicaments
VANCOUVER, Colombie–Britannique, 18 déc. 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), leader mondial dans la fabrication d’ingrédients pharmaceutiques actifs (IPA) à base de [...] Read more »
Brains Bioceutical weitet das branchenführende Cannabinoid-Angebot auf D9-THC und CBN aus, um neue Grenzen in der Wirkstoffentwicklung zu erschließen
VANCOUVER, British Columbia, Dec. 18, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), ein weltweit führendes Unternehmen für natürliche GMP–konforme cannabinoide Pharmawirkstoffe (API), gibt die [...] Read more »
Brains Bioceutical Expande Oferta de Canabinóides Líder do Setor com D9-THC e CBN, Abrindo Novas Fronteiras para o Desenvolvimento de Medicamentos
VANCOUVER, British Columbia, Dec. 18, 2024 (GLOBE NEWSWIRE) — A Brains Bioceutical Corp. (Brains Bio), líder global em Ingredientes Farmacêuticos Ativos (APIs) de canabinóides naturais e compatíveis com [...] Read more »
Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development
VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), a global leader in natural, GMP–compliant cannabinoid Active Pharmaceutical Ingredients (APIs), announces the expansion of its [...] Read more »